Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization.
Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization.
复制标题
DOI：
10.1073/pnas.97.7.3422
复制
发表时间：
2000-03
影响因子：
11.1
通讯作者：
C. Kalka;H. Masuda;Tomono Takahashi;W. Kalka-Moll;Marcy Silver;M. Kearney;Tong Li;J. Isner
中科院分区：
文献类型：
--
作者：
C. Kalka;H. Masuda;Tomono Takahashi;W. Kalka-Moll;Marcy Silver;M. Kearney;Tong Li;J. Isner
动物研究和人类的初步结果表明，下肢和心肌缺血可以通过血管生成细胞因子治疗来减轻。然而，能够对可用水平的血管生成生长因子作出反应的内皮细胞的常驻群体可能潜在地限制细胞因子补充增强组织新血管形成的程度。因此，我们将人内皮祖细胞（hEPCs）移植到后肢缺血的无胸腺裸鼠体内。缺血后肢的血流恢复和毛细血管密度明显改善，肢体丧失率明显降低。因此，离体扩增的hEPCs可作为治疗性新血管形成的“供应侧”策略。
Animal studies and preliminary results in humans suggest that lower extremity and myocardial ischemia can be attenuated by treatment with angiogenic cytokines. The resident population of endothelial cells that is competent to respond to an available level of angiogenic growth factors, however, may potentially limit the extent to which cytokine supplementation enhances tissue neovascularization. Accordingly, we transplanted human endothelial progenitor cells (hEPCs) to athymic nude mice with hindlimb ischemia. Blood flow recovery and capillary density in the ischemic hindlimb were markedly improved, and the rate of limb loss was significantly reduced. Ex vivo expanded hEPCs may thus have utility as a "supply-side" strategy for therapeutic neovascularization.